Research programme: regenerative hearing therapeutics - Sound Pharmaceuticals

Drug Profile

Research programme: regenerative hearing therapeutics - Sound Pharmaceuticals

Alternative Names: SPI 128; SPI 5505; SPI-5557

Latest Information Update: 18 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sound Pharmaceuticals
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sensorineural hearing loss

Most Recent Events

  • 18 Jul 2016 Preclinical development is ongoing (Sound Pharmaceuticals pipeline, July 2016)
  • 18 Jul 2016 Sound Pharmaceuticals announces intention to submit an IND in Sensorineural hearing loss in the fourth quarter of 2017 (Sound Pharmaceuticals pipeline, July 2016)
  • 30 Nov 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top